Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Inability of il-2 and il-10 to counteract b-cell clonal deletion

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Cuende, E.
  • Kroemer, G.
  • Alonso, J. M.
  • Nemazee, David
  • Martinez, C.
  • Alesmartinez, J. E.

publication date

  • June 1992

journal

  • Cellular Immunology  Journal

abstract

  • The B cell antigen receptor (BCR) delivers inhibitory signals in nascent B cells leading to the establishment of tolerance via clonal deletion or clonal anergy depending upon the type of antigen to which the B cells are exposed. In previous work, it has been demonstrated that activated Th2 cells, as well as some recombinant lymphokines, prevent the inhibition of growth and subsequent cell death induced through the BCR in model B cell lymphomas. Herein, we extend this work to another Th2 lymphokine, IL-10, that in contrast to IL-4 does not interfere with the deletion promoted by IgM crosslinking. The effect of individual lymphokines has also begun to be analyzed in a transgenic model of B cell clonal deletion. To this end, we have administered a recombinant vaccinia virus producing human IL-2 to mice expressing an autoreactive H-2Kk,b-specific transgenic IgMk and found that IL-2 does not abrogate B cell deletion in vivo.

subject areas

  • Animals
  • Antibodies, Bacterial
  • B-Lymphocytes
  • Cell Death
  • Immunoglobulin M
  • Interleukin-10
  • Interleukin-2
  • Lymphocyte Activation
  • Lymphoma, B-Cell
  • Mice
  • Mice, Transgenic
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 0008-8749

Digital Object Identifier (DOI)

  • 10.1016/0008-8749(92)90271-p

PubMed ID

  • 1586962
scroll to property group menus

Additional Document Info

start page

  • 94

end page

  • 102

volume

  • 142

issue

  • 1

©2021 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support